461 related articles for article (PubMed ID: 33903122)
21. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
[No Abstract] [Full Text] [Related]
22. HBX-induced miR-5188 impairs FOXO1 to stimulate β-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma.
Lin X; Zuo S; Luo R; Li Y; Yu G; Zou Y; Zhou Y; Liu Z; Liu Y; Hu Y; Xie Y; Fang W; Liu Z
Theranostics; 2019; 9(25):7583-7598. PubMed ID: 31695788
[TBL] [Abstract][Full Text] [Related]
23. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells.
Wang R; Sun Q; Wang P; Liu M; Xiong S; Luo J; Huang H; Du Q; Geller DA; Cheng B
Oncotarget; 2016 Feb; 7(5):5754-68. PubMed ID: 26735577
[TBL] [Abstract][Full Text] [Related]
24. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
25. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells.
Xia W; Lo CM; Poon RYC; Cheung TT; Chan ACY; Chen L; Yang S; Tsao GSW; Wang XQ
Oncotarget; 2017 Jun; 8(24):38811-38824. PubMed ID: 28415588
[TBL] [Abstract][Full Text] [Related]
26. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
27. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.
Cheng BY; Lau EY; Leung HW; Leung CO; Ho NP; Gurung S; Cheng LK; Lin CH; Lo RC; Ma S; Ng IO; Lee TK
Cancer Res; 2018 May; 78(9):2332-2342. PubMed ID: 29483095
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance.
Zhao W; Ma B; Tian Z; Han H; Tang J; Dong B; An G; Cao B; Wang B
Br J Cancer; 2021 Mar; 124(7):1237-1248. PubMed ID: 33473171
[TBL] [Abstract][Full Text] [Related]
29. RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin-ferroptosis axis.
Li Z; Caron de Fromentel C; Kim W; Wang WH; Sun J; Yan B; Utturkar S; Lanman NA; Elzey BD; Yeo Y; Zhang H; Kazemian M; Levrero M; Andrisani O
Cell Death Dis; 2023 Nov; 14(11):786. PubMed ID: 38036507
[TBL] [Abstract][Full Text] [Related]
30. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
[TBL] [Abstract][Full Text] [Related]
31. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
32. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
[TBL] [Abstract][Full Text] [Related]
34. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
35. Zinc finger protein X-linked promotes expansion of EpCAM
Wang C; Fu SY; Wang MD; Yu WB; Cui QS; Wang HR; Huang H; Dong W; Zhang WW; Li PP; Lin C; Pan ZY; Yang Y; Wu MC; Zhou WP
Mol Oncol; 2017 May; 11(5):455-469. PubMed ID: 28156061
[TBL] [Abstract][Full Text] [Related]
36. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway.
Yang C; Cai WC; Dong ZT; Guo JW; Zhao YJ; Sui CJ; Yang JM
Gene; 2019 Mar; 687():73-81. PubMed ID: 30391438
[TBL] [Abstract][Full Text] [Related]
37. Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target.
Ma XL; Sun YF; Wang BL; Shen MN; Zhou Y; Chen JW; Hu B; Gong ZJ; Zhang X; Cao Y; Pan BS; Zhou J; Fan J; Guo W; Yang XR
BMC Cancer; 2019 Aug; 19(1):760. PubMed ID: 31370822
[TBL] [Abstract][Full Text] [Related]
38. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
39. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
[TBL] [Abstract][Full Text] [Related]
40. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]